Skip to main content
. 2013 Jun 12;169(5):953–962. doi: 10.1111/bph.12193

Figure 2.

Figure 2

Effects of oral treatment with LASSBio-1359 (50 mg·kg−1, p.o.) for 2 weeks on RVSP and on right ventricular (RV) hypertrophy in MCT-injected rats. (A) Representative tracings of RVSP of rats injected with saline (control), MCT, MCT + vehicle (DMSO), and MCT + LASSBio-1359, respectively. (B) MCT-injected rats developed PAH, as shown by the increased RVSP. Oral treatment with LASSBio-1359 (50 mg·kg−1·day−1) reversed the development of PAH. (C) RV weight to left ventricle + septum weight ratio [RV/LV + S]. (D) RV weight to body weight ratio [RV/BW]. Treatment with LASSBio-1359 decreased the RV hypertrophy. Each column represents the mean ± SEM (n = 6). **P < 0.01, ***P < 0.001 versus control; †P < 0.05 versus MCT; ‡P < 0.05 versus MCT + vehicle.